Abbreviated Name

Lung Ref Set A App: Hirschowitz (2009)

Lead Investigator

Hirschowitz, Edward — University of Kentucky

Coordinating Investigator

Zheng, Yingye — Fred Hutchinson Cancer Center

Involved Investigators

• Srivastava, Sudhir — National Cancer Institute
• Ujhazy, Peter — National Cancer Institute
• Hirschowitz, Edward — University of Kentucky
• Zheng, Yingye — Fred Hutchinson Cancer Center

Abstract

No abstract availalbe.

Aims

Aim 1. To pre-validate assay performance in a high-risk clinical population from an alternate demographic. We intend to validate the predictive accuracy of our markers for clinically diagnosed lung cancer, identify the limits of the assay in individuals with benign lung disease, and determine marker specificity for lung vs. other cancers. Pre-validation will define performance in samples from an alternate demographic and generate classifiers with which to construct optimalperformance criteria that can be applied to class prediction for subsequent blinded analysis of a larger EDRN clinical reference set.

Analytic Method

Assay. The diagnostic chip includes capture proteins for the most predictive markers and empty T7 phage controls in replicates of eight, randomly distributed across the chip. The methodology for all studies will be identical to that described in published manuscripts and preliminary results section.

Comments

No comments available.

Outcome

25 markers of circulating antibodies for tumor proteins were evaluated on the EDRN Lung reference Set A. Discrimination between (a) 222 cases of lung cancer and 195 high-risk controls and between b) 222 cases of lung cancer and 24 other-cancers were evaluated. AUCs demonstrated were (a) between 0.51 and 0.56 (22 mkrs), with 2 0.57 and 1 0.58 and (b) between 0.53 and 0.56 (all 25 mkrs).

Secure Outcome

No secure outcome available.

Publications

• No publications available at this time for this protocol.

Biomarkers

• T7 (25 markers)

Data Collections

• No data collections available at this time for this protocol.

Start Date

Mar 26 2009

Estimated Finish Date

Mar 25 2010

Finish Date

Feb 27 2012

Protocol ID

279

Protocol Type

Reference Set

Fields of Research

• Proteomics

Collaborative Group

Lung and Upper Aerodigestive Cancers Research Group

Cancer Types

• Malignant neoplasm of bronchus and lung

Phased Status

1